| Kimberly Benning, LAC | |
|
110 Pearson, Benton, AR 72015-4436 | |
| (501) 315-4224 | |
| (501) 778-0450 |
| Full Name | Kimberly Benning |
|---|---|
| Gender | Female |
| Speciality | Counselor - Mental Health |
| Location | 110 Pearson, Benton, Arkansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235873878 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | A2204009 (Arkansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kimberly Benning, LAC 110 Pearson, Benton, AR 72015-4436 Ph: (501) 315-4224 | Kimberly Benning, LAC 110 Pearson, Benton, AR 72015-4436 Ph: (501) 315-4224 |
News Archive
A review and analysis of previously published studies finds that patients, research participants and journal readers believe financial relationships between medicine and industry should be disclosed, in part because those financial ties may influence research and clinical care, according to a report in the April 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Scientists from A*STAR's Singapore Institute for Clinical Sciences (SICS), together with clinical collaborators from London , discovered for the first time that children and young patients with chronic Hepatitis B Virus infection (HBV carriers) do have a protective immune response, contrary to current belief, and hence can be more suitable treatment candidates than previously considered.
Elan Corporation plc and Celgene Corporation, today announced that Elan subsidiary Elan PharmaInternational Limited has entered into a settlement and license agreement with Celgene Corporation resolving the patent infringement litigation involving ABRAXANE.
Braeburn Pharmaceuticals and Camurus announce that the first patient has been randomized in the double blind Phase 3 efficacy trial of CAM2038 in opioid-dependent patients. CAM2038 medications are designed for long-acting weekly and monthly administration.
Fluoxetine was the first drug approved by the FDA for major depressive disorder (MDD) in children and adolescents, and to this date, it remains one of only two selective serotonin reuptake inhibitors (SSRIs) registered for treatment of MDD in children and adolescents, despite reports that indicate this class of drugs is associated with side effects, such as agitation, hostility and aggression.
› Verified 1 days ago
Mrs. Ashleigh Rosinbaum, Counselor Medicare: Not Enrolled in Medicare Practice Location: 3214 Winchester, Benton, AR 72015 Phone: 501-326-6160 Fax: 501-326-6161 | |
Mrs. Lisa Dansby Williams, MS, LAC Counselor Medicare: Not Enrolled in Medicare Practice Location: 100 Rivendell Dr, Benton, AR 72015 Phone: 501-316-1255 Fax: 501-316-2221 | |
Michelle Leann Crews, Counselor Medicare: Not Enrolled in Medicare Practice Location: 3214 Winchester, Benton, AR 72015 Phone: 501-326-6160 | |
Elizabeth Sara Farmer, LCSW Counselor Medicare: Not Enrolled in Medicare Practice Location: 200 N Market St, Benton, AR 72015 Phone: 501-847-2229 | |
Belinda L Williams, Counselor Medicare: Not Enrolled in Medicare Practice Location: 100 Rivendell Dr, Benton, AR 72019 Phone: 501-316-1255 | |
Brian Kosters, CMP Counselor Medicare: Medicare Enrolled Practice Location: 6701 Highway 67, Benton, AR 72015 Phone: 501-315-3344 | |
Mrs. Amy Bradshaw, LCSW Counselor Medicare: Not Enrolled in Medicare Practice Location: 307 E Sevier St, Benton, AR 72015 Phone: 501-315-4224 Fax: 501-776-0411 |